# HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours

> **NCT06708663** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hangzhou Hanx Biopharmaceuticals, Ltd.** · enrollment: 124 (estimated)

## Conditions studied

- Biliary Tract Cancer
- Melanoma

## Interventions

- **DRUG:** HX009+IN10018

## Key facts

- **NCT ID:** NCT06708663
- **Lead sponsor:** Hangzhou Hanx Biopharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-17
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06708663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06708663, "HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06708663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*